Moreover, in current study, ROC successfully identified predictive cut-points for TLG (42.35) and MTV (12.75) that were able to discriminate positive and negative HER2 expression in breast cancer patients (p-value=0.002 and 0.004, respectively). Here, ERBB2 is linked to breast carcinoma.